Light deficiency confers breast cancer risk by endocrine disorders

Recent Patents on Anti-Cancer Drug Discovery

Volumn 7, Issue 3, 2012, Pages 337-344

  Suba, Zsuzsanna ^a  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

Author keywords

African American women; Breast cancer risk; Darkness; Estrogen; Hypothyroidism; Insulin resistance; Melatonin; vitamin D

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; INSULIN; MELATONIN; THYROXINE; VITAMIN D;

AFRICAN AMERICAN; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER STAGING; CAUCASIAN; CIRCADIAN RHYTHM; CORRELATION ANALYSIS; DARKNESS; EARLY DIAGNOSIS; ENDOCRINE DISEASE; ESTROGEN DEFICIENCY; ETHNIC DIFFERENCE; EUROPE; FEMALE; HORMONE SYNTHESIS; HUMAN; HYPOTHYROIDISM; IMMIGRANT; INSULIN RESISTANCE; LIGHT EXPOSURE; MELATONIN SYNTHESIS; NEGRO; NONHUMAN; NORTH AMERICA; PRIORITY JOURNAL; RACE DIFFERENCE; RISK ASSESSMENT; SKIN PIGMENTATION; UNITED STATES; VITAMIN D DEFICIENCY;

AFRICAN AMERICANS; BREAST NEOPLASMS; CARCINOMA; ENDOCRINE SYSTEM DISEASES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INCIDENCE; LIGHT; PHOTOPERIOD; RISK FACTORS; SUNLIGHT; UNITED STATES;

EID: 84867559102     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489212801820048     Document Type: Article

References (108)

1. Szabolcs O. Cancer epidemiology in Hungary and the Béla Johan National Program for the Decade of Health. Pathol Oncol Res 2003; 9(2): 126-30.
2. Suba Z. Common soil of smoking-associated and hormone-related cancers: Estrogen deficiency. Oncol Rev 2010; 4(2):73-87.
3. Wynder EL, Bross IJ, Feldman RM. A study of the etiological factors in cancer of the mouth. Cancer 1957; 10: 1300-23.
4. thed. Philadelphia, Saunders Elsevier, 2007, pp. 711-50.
5. Amend K, Hicks D, Ambrosone CB. Breast cancer in African-American women: Differences in tumor biology from European-American women. Cancer Res 2006; 66(17): 8327-30.
6. Chandran U, Hirshfield KM, Bandera EV. The role of anthropometric and nutritional factors on breast cancer risk in African-American women. Public Health Nutr 2012; 15(4): 738-48.
7. Amirikia KC, Mills P, Bush J, Newman LA. Higher populationbased incidence rates of triple-negative breast cancer among young African-American women: Implications for breast cancer screening recommendations. Cancer 2011; 117(12): 2747-53.
8. Stark A, Stapp R, Raghunathan A, Yan X, Kirchner HL, Griggs J, et al. Disease-free probability after the first primary ductal carcinoma in situ of the breast: A comparison between African-American and White-American women. Breast Cancer Res Treat 2012; 131(2): 561-70.
9. Holmes L Jr, Opara F, Hossain J. A five-year breast cancer-specific survival disadvantage of African American women. Afr J Reprod Health 2010; 14(3): 195-200.
10. Field LA, Love B, Deyarmin B, Hooke JA, Shriver CD, Ellsworth RE. Identification of differentially expressed genes in breast tumors from African-American compared with Caucasian women. Cancer 2012; 118(5): 1334-44.
11. Fedewa SA, Edge SB, Stewart AK, Halpern MT, Marlow NM, Ward EM. Race and ethnicity are associated with delays in breast cancer treatment (2003-2006). J Health Care Poor Underserved 2011; 22(1): 128-41.
12. Sail K, Franzini L, Lairson D, Du X. Differences in treatment and survival among African-American and Caucasian women with early stage operable breast cancer. Ethn Health 2011; Nov 9 [Epub ahead of print].
13. Suba Z. Insulin resistance, hyperinsulinemia and cancer risk. Chapter 2. In: Ed. Suba Z. Estrogen versus Cancer. New York, Nova Science Publishers Inc. 2009, pp. 19-40.
14. Lukanova A, Björ O, Kaaks R, Lenner P, Lindahl B, Hallmans G, et al. Body mass index and cancer: Results from the Northern Sweden Health and Disease Cohort. Int J Cancer 2006; 118(2): 458-66.
15. Sturgeon SR, Potischman N, Malone KE, Dorgan JF, Daling J, Schairer C, et al. Serum levels of sex hormones and breast cancer risk in premenopausal women: A case-control study (USA). Cancer Causes Control 2004; 15(1): 45-53.
16. Mousavi SM, Sundquist J, Hemminki K. Nasopharyngeal and hypopharyngeal carcinoma risk among immigrants in Sweden. Int J Cancer 2010; 127(12): 2888-92.
17. Hemminki K, Mousavi SM, Sundquist J, Brandt A. Does the breast cancer age at diagnosis differ by ethnicity? A study on immigrants to Sweden. Oncologist 2011; 16(2): 146-54.
18. Stevens RG. Electric power use and breast cancer: A hypothesis. Am J Epidemiol 1987; 125(4): 556-61.
19. Rohr UD, Herold J. Melatonin deficiencies in women. Maturitas 2002; 41: S85-S104.
20. Vriend J, Bertalanffy FD, Ralcewicz TA. The effects of melatonin and hypothyroidism on estradiol and gonadotropin levels in female Syrian hamsters. Biol Reprod 1987; 36(3): 719-28.
21. Goericke-Pesch S. Reproduction control in cats: New developments in non-surgical methods. J Feline Med Surg 2010; 12(7): 539-46.
22. Luboshitzky R, Shen-Orr Z, Ishai A, Lavie P. Melatonin hypersecretion in male patients with adult-onset idiopathic hypogonadotropic hypogonadism. Exp Clin Endocrinol Diabetes 2000; 108(2): 142-5.
23. Viswanathan AN, Schernhammer ES. Circulating melatonin and the risk of breast and endometrial cancer in women. Cancer Lett 2009; 281(1): 1-7.
24. Bartsch C, Bartsch, Bellmann O, Lippert TH. Depression of serum melatonin in patients with primary breast cancer is not due to an increased peripheral metabolism. Cancer 1991; 67(6): 1681-4.
25. Dreher F, Gabard B, Schwindt DA, Maibach HI. Topical melatonin in combination with vitamin E and C protects skin from ultravioletinduced erythema. Br J Dermatol 1998; 139(2): 332-9.
26. Cos S, González A, Martínez-Campa C, Mediavilla MD, Alonso-González C, Sánchez-Barceló EJ. Melatonin as a selective estrogen enzyme modulator. Curr Cancer Drug Targets 2008; 8(8): 691-702.
27. Cos S, Gonzalez A, Martínez-Campa C, Mediavilla MD, Alonso-González C, Sanchez Barceló EJ. Estrogen signaling pathway: A link between breast cancer and melatonin oncostatic actions. Cancer Detect Prev 2006; 30(2): 118-28.
28. Sánchez-Barceló EJ, Cos S, Mediavilla MD, Martinez-Campa C, González A, Alonso-Gozález C. Melatonin-estrogen interactions in breast cancer. J Pineal Res 2005; 38(4): 217-22.
29. Hill SM, Frasch T, Xiang S, Yuan L, Duplessis T, Mao L. Molecular mechanisms of melatonin anticancer effects. Integr Cancer Ther 2009; 8(4): 337-46.
30. Martínez-Campa C, Alonso-González C, Mediavilla MD, Cos S, González A, Ramos S, et al. Melatonin inhibits both ER alpha activation and breast cancer cell proliferation induced by a metalloestrogen, cadmium. J Pineal Res 2006; 40(4): 291-6.
31. Watanabe M, Kobayashi Y, Takahashi N, Kiguchi K, Ishizuka B. Expression of melatonin receptor (MT1) and interaction between melatonin and estrogen in endometrial cancer cell line. J Obstet Gynaecol Res 2008; 34(4): 567-73.
32. Girgert R, Hanf V, Emons G, Gründker C. Membrane-bound melatonin receptor MT1 down-regulates estrogen responsive genes in breast cancer cells. J Pineal Res 2009; 47(1): 23-31.
33. Sanchez-Barcelo EJ, Mediavilla MD, Alonso-Gonzalez C, Rueda N. Breast cancer therapy based on melatonin. Recent Pat Endocr Metab Immune Drug Discov 2012; Feb 20 [Epub ahead of print].
34. Peschke E, Mühlbauer E. New evidence for a role of melatonin in glucose regulation. Best Pract Res Clin Endocrinol Metab 2010; 24(5): 829-41.
35. Cagnacci A, Arangino S, Renzi A, Paoletti AM, Melis GB, Cagnacci P. Influence of melatonin administration on glucose tolerance and insulin sensitivity of postmenopausal women. Clin Endocrinol 2001; 54(3): 339-46.
36. Shieh JM, Wu HT, Cheng KC, Cheng JT. Melatonin ameliorates high fat diet-induced diabetes and stimulates glycogen synthesis via a PKCzeta-Akt-GSK3beta pathway in hepatic cells. J Pineal Res 2009; 47(4): 339-44.
37. Nishida S, Segawa T, Murai I, Nakagawa S. Long-term melatonin administration reduces hyperinsulinemia and improves the altered fatty-acid compositions in type 2 diabetic rats via the restoration of Delta-5 desaturase activity. J Pineal Res 2002; 32(1): 26-33.
38. Sartori C, Dessen P, Mathieu C, Monney A, Bloch J, Nicod P. Melatonin improves glucose homeostasis and endothelial vascular function in high-fat diet-fed insulin-resistant mice. Endocrinology 2009; 150(12): 5311-7.
39. Contreras-Alcantara S, Baba K, Tosini G. Removal of melatonin receptor type 1 induces insulin resistance in the mouse. Obesity (Silver Spring) 2010; 18(9): 1861-3.
40. Mühlbauer E, Gross E, Labucay K, Wolgast S, Peschke E. Loss of melatonin signaling and its impact on circadian rhythms in mouse organs regulating blood glucose. Eur J Pharmacol 2009; 606(1-3): 61-71.
41. Espino J, Pariente JA, Rodriguez AB. Role of melatonin on diabetes-related metabolic disorders. World J Diabetes 2011; 2(6): 82-91.
42. Bloomgarden ZT. Second World Congress on the Insulin Resistance Syndrome: Mediators, pediatric insulin resistance, the polycystic ovary syndrome, and malignancy. Diabetes Care 2005; 28(8): 1821-30.
43. Suba Z. Insulin resistance and oral cancer risk. Cancer Res J 2009; 3(1-2): 1-22.
44. Suba Z. Interplay between insulin resistance and estrogen deficiency as co-activators in carcinogenesis. Pathol Oncol Res 2011; 18: 123-33.
45. Suba Z. Insulin Resistance, Estrogen Deficiency and Cancer Risk. In: Suba Z Ed. Estrogen versus Cancer. Chapter 7. New York, Nova Science Publishers Inc., 2009, pp. 127-46.
46. Doyle SL, Donohoe CL, Lysaght J, Reynolds JV. Visceral obesity, metabolic syndrome, insulin resistance and cancer. Proc Nutr Soc 2012; 71(1): 181-9.
47. Grote VA, Becker S, Kaaks R. Diabetes mellitus type 2: An independent risk factor for cancer? Exp Clin Endocrinol Diabetes 2010; 118(1): 4-8.
48. Rosato V, Bosetti C, Talamini R, Levi F, Montella M, Giacosa A, et al. Metabolic syndrome and the risk of breast cancer in postmenopausal women. Ann Oncol 2011; 22(12): 2687-92.
49. Sieri S, Muti P, Claudia A, Berrino F, Pala V, Grioni S, et al. Prospective study on the role of glucose metabolism in breast cancer occurrence. Int J Cancer 2012; 130(4): 921-9.
50. Abbasi M, Tarafdari A, Esteghamati A, Vejdani K, Nakhiavani M. Insulin resistance and breast carcinogenesis: A cross-sectional study among Iranian women with breast mass. Metab Syndr Relat Disord 2010; 8(5): 411-6.
51. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, et al. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2009; 101(1): 48-60.
52. Colonna SV, Douglas Case L, Lawrence JA. A retrospective review of the metabolic syndrome in women diagnosed with breast cancer and correlation with estrogen receptor. Breast Cancer Res Treat 2012; 131(1): 325-31.
53. Vona-Davis L, Howard-McNatt M, Rose DP. Adiposity, type-2 diabetes and the metabolic syndrome in breast cancer. Obes Rev 2007; 8(5): 395-408.
54. Arif JM, Al-SaifAM, Al-Karrawi MA, Al-Sagair OA. Causative relationship between diabetes mellitus and breast cancer in various regions of Saudi Arabia: An overview. Asian Pac J Cancer Prev 2011; 12(3): 589-92.
55. Kalla Singh S, Brito C, Tan QW, De León M, De León D. Differential expression and signaling activation of insulin receptor isoforms A and B: A link between breast cancer and diabetes. Growth Factors 2011; 29(6): 278-89.
56. Suba Z. Insulin Resistance and Oral Cancer Risk. Chapter 4. In: Watanabe HS. Ed. Horizons in Cancer Research, Vol. 43. New York, Nova Science Publishers Inc., 2011; pp. 77-97.
57. Rose DP, Haffner SM, Baillargeon J. Adiposity, the metabolic syndrome, and breast cancer in African-American and white American women. Endocr Rev 2007; 28(7): 763-77.
58. Falkner B, Sherif K, Sumner A, Kushner H. Hyperinsulinism and sex hormones in young adult African Americans. Metabolism 1999; 48(1): 107-12.
59. Harris SS. Does vitamin D deficiency contribute to increased rates of cardiovascular disease and type 2 diabetes in African Americans? Am J Clin Nutr 2011; 93: 1175S-8S.
60. Suba Z, Kásler M. Interactions of insulin and estrogen in the regulation of cell proliferation and carcinogenesis. Orv Hetil (in Hungarian) 2012; 153(4): 47-58.
61. Dalton, J.T., Dodson, S., Steiner, M.S. Selective androgen receptor modulators for treating diabetes. US20110237664 (2011).
62. Conroy SM, Maskarinec G, Wilkens LR, White KK, Henderson BE, Kolonel LN. Obesity and breast cancer survival in ethnically diverse postmenopausal women: The Multiethnic Cohort Study. Breast Cancer Res Treat 2011; 129(2): 565-74.
63. Sarkissyan M, Wu Y, Vadgama JV. Obesity is associated with breast cancer in African-American women but not Hispanic women in South Los Angeles. Cancer 2011; 117(16): 3814-23.
64. Sandyk R, Anastasiadis PG, Anninos PA, Tsagas N. Is the pineal gland involved in the pathogenesis of endometrial carcinoma. Int J Neurosci 1992; 62(1-2): 89-96.
65. Grant SG, Melan MA, Latimer JJ, Witt-Enderby PA. Melatonin and breast cancer: Cellular mechanisms, clinical studies and future perspectives. Expert Rev Mol 2009; 11: e5.
66. Gonzalez A, Cos S, Martinez-Campa C, Alonso-Gonzalez C, Sanchez-Mateos S, Mediavilla MD. Selective estrogen enzyme modulator actions of melatonin in human breast cancer cells. J Pineal Res 2008; 45(1): 86-92.
67. Abd-Allah AR, El-Sayed el SM, Abdel-Wahab MH, Hamada FM. Effect of melatonin on estrogen and progesterone receptors in relation to uterine contraction in rats. Pharmacol Res 2003; 47(4): 349-54.
68. Hayashi K, Okatani Y. Mechanisms underlying the effects of estrogen on nocturnal melatonin synthesis in peripubertal female rats: Relation to norepinephrine and adenylatecyclase. J Pineal Res 1999; 26(3): 178-83.
69. Grin W, Grünberger W. A significant correlation between melatonin deficiency and endometrium cancer. Gynecol Obstet Invest 1998; 45(1): 62-5.
70. Bartsch C, Bartsch H, Blask DE, Cardinali DP, Hrushewsky WJM, Mecke D. The Pineal Gland and Cancer. Springer: Berlin 2001.
71. Ohashi Y, Okamoto N, Uchida K, Iyo M, Mori N, Morita Y. Differential pattern of the circadian rhythm of serum melatonin in young and elderly healthy subjects. Biol Signals 1997; 6(4-6): 301-6.
72. Cameron, K.O., Dasliva-Jardine, P.A., Ke, H.Z., Rosati, R.L. Estrogen agonists/antagonists for preventing breast cancer. Compounds of this formula 1 are useful for preventing breast cancer. US20010025051 (2001).
73. Bellipani G, Bianchi P, Pierpaoli W, Bulian D, Ilyia E. Effects of melatonin in perimenopausal women and menopausal women: A randomized and placebo controlled study. Exp Gerontol 2001; 36(2): 297-310.
74. Röjdmark S, Berg A, Rössner S, Wetterberg L. Nocturnal melatonin secretion in thyroid disease and in obesity. Clin Endocrinol 1991; 35(1): 61-5.
75. Boucai L, Surks MI. Reference limits of serum TSH and free T4 are significantly influenced by race and age in an urban outpatient medical practice. Clin Endocrinol (Oxf) 2009; 70(5): 788-93.
76. Smyth PP. The thyroid and breast cancer: A significant association? Ann Med 1997; 29(3): 189-91.
77. Turken O, Narin Y, Demirbas S, Onde ME, Sayan O, Kandemir EG, et al. Breast cancer in association with thyroid disorders. Breast Cancer Res 2003; 5(5): R110-3.
78. Kuijpens JL, Nyklictek I, Louwman MW, Weetman TA, Pop VJ, Coebergh JW. Hypothyroidism might be related to breast cancer in post-menopausal women. Thyroid 2005; 15(11): 1253-9.
79. Martinez-Inglesias O, Garcia-Silva S, Regadera J, Aranda A. Hypothyroidism enhances tumor invasiveness and metastasis development. PLoS One 2009; 4(7): e6428.
80. Jeschke, U., Ditsch, N., Mayr, D. Thyroid hormone receptor expression for the diagnosis and prognosis on breast cancer and ovarian cancer. WO2011135091 (2011).
81. Rao VR, Lakshmi A, Sadhnani MD. Prevalence of hypothyroidism in recurrent pregnancy loss in first trimester. Indian J Med Sci 2008; 62(9): 357-61.
82. Dobnig H. A review of the health consequences of the vitamin D deficiency pandemic. J Neurol Sci 2011; 311(1-2): 15-8.
83. White JH. Vitamin D as an inducer of cathelicidin antimicrobial peptide expression: Past, present and future. J Steroid Biochem Mol Biol 2010; 121(1-2): 234-8.
84. Melamed ML, Michos ED, Post W, Astor B. 25-Hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008; 168(15): 1629-37.
85. Grant WB, Juzeninene A, Moan JE. Review article: Health benefit of increased serum 25 (OH)D levels from oral intake and ultraviolet-B irradiance in the Nordic countries. Scand J Public Health 2011; 39(1): 70-8.
86. Nazarian S, St Peter JV, Boston RC, Jones SA, Mariash CN. Vitamin D3 supplementation improves insulin sensitivity in subjects with impaired fasting glucose. Transl Res 2011; 158(5): 276-81.
87. Giovanucci E. The epidemiology of vitamin D and cancer incidence and mortality: A review (United States). Cancer Causes Control 2005; 16(2): 83-95.
88. Olson ML, Maalouf NM, Oden JD, White PC, Hutchinson MR. Vitamin D deficiency in obese children and its relationship to glucose homeostasis. J Clin Endocrinol Metab 2012; 97(1): 279-85.
89. Grundman M, von Versen-Höynck F. Vitamin D-roles in women's reproductive health? Reprod Biol Endocrinol 2011; 9: 146.
90. Henner, W.D., Beer, T.M. Vitamin D and its analogs in the treatment of tumors and other hyperproliferative disorders. EP1064000 (2011).
91. Auerbach, A.H., Belldegrun, A.S. Use of a vitamin D compound and an additional therapeutic agent for the treatment of cancer. EP2425874 (2012).
92. Mitchell D. The relationship between vitamin D and cancer. Clin J Oncol Nurs 2011; 15(5): 557-60.
93. Pilz S, Tomaschitz A, Obermayer-Pietsch B, Dobnig H, Pieber TR. Epidemiology of vitamin D insufficiency and cancer mortality. Anicancer Res 2009; 29(9): 3699-704.
94. Arends J. Vitamin D in oncology. Forsch Komplementmed 2011; 18(4):176-84
95. Crew KD, Gammon MD, Steck SE, Hershman DL, Cremers S, Dworakowski E, et al. Association between plasma 25-hydroxyvitamin D and breast cancer risk. Cancer Prev Res (Phila) 2009; 2(6): 598-604.
96. Grant WB, Peiris AN. Possible role of serum 25-hydroxyvitamin D in black-white health disparities in the United States. J Am Med Dir Assoc 2010; 11(9): 617-28.
97. Stevens RG. Working against our endogenous circadian clock: Breast cancer and electric lighting in the modern world. Mutat Res 2009; 680(1-2): 106-8.
98. Cohen M, Lippman M, Chabner B. Role of pineal gland in aetiology and treatment of breast cancer. Lancet 1978; 2(8094): 814-6.
99. Bonde JP, Hansen J, Kolstad HA, Mikkelsen S, Olsen JH, Blask DE, et al. Work at night and breast cancer-report on evidencebased options for preventive actions. Scand J Work Environ Health 2012; Feb 20 [Epub ahead of print].
100. Langley AR, Graham CH, Grundy AL, Tranmer JE, Richardson H, Aronson KJ. A cross sectional study of breast cancer biomarkers among shift working nurses. BMJ Open 2012; 2(1): e000532.
101. Grundy A, Tranmer J, Richardson H, Graham CH, Aronson KL. The influence of light and night exposure on melatonin levels among Canadian rotating shift nurses. Cancer Epidemiol Biomarkers Prev 2011; 20(11): 2404-12.
102. Brudnowska J, Peplonska B. Night shift work and cancer risk: A literature review (Polish). Med Pr 2011; 62(3): 323-38.
103. Blask DE, Brainard GC, Dauchy RT, Hanifin JP, Davidson LK, Krause JA, et al. Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude rats. Cancer Res 2005; 65(23): 11174-84.
104. Kliukiene J, Tynes T, Andersen A. A risk of breast cancer among women with visual impairment. Br J Cancer 2001; 84(3): 397-9.
105. Hahn RA. Profound bilateral blindness and incidence of breast cancer. Epidemiology 1991; 2(3): 208-10.
106. Feychting M, Osterlund B, Ahlbom A. Reduced cancer incidence among the blind. Epidemiology 1998; 9(5): 490-4.
107. Verkasalo PK, Pukkala E, Stevens RG, Ojamo M, Rudanko SL. Inverse association between breast cancer incidence and degree of visual impairment in Finland. Br J Cancer 1999; 80(9): 1459-60.
108. Powell, M.I. Diagnosis and treatment of cancer related to human dormancy. US8075902 (2011).